It was announced early September 9, 2011, that The Assistance Fund has created a new program to supply premium assistance to Multiple Sclerosis patients. For more information, see the press release below: Announcing The Assistance Fund Multiple Sclerosis Premium Assistance Program
Alemtuzumab and laquinimod results released Sanofi and its subsidiary Genzyme announced the results of a two-year study of 581 people with relapsing-remitting MS testing their experimental intravenous therapy alemtuzumab. Meanwhile, Teva Pharmaceutical Industries Ltd. and Active Biotech announced the results of a study involving more than 1,300 people with relapsing-remitting MS testing their oral drug laquinimod Read More...
HONOLULU – Oral therapies for relapsing-remitting multiple sclerosis that are in the development pipeline have neurologists feeling both excited and a bit apprehensive. "There are a whole slew of orals coming," Dr. Mariko Kita said in an interview at the annual meeting of the American Academy of Neurology Read More...
The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS). “Gilenya is the first oral drug that can slow the progression of disability and reduce the frequency and severity of symptoms in MS, offering patients an alternative to currently available injectable therapies,” said Russell Katz, M Read More...
Merck Serono: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS Geneva, Switzerland, July 28, 2010 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS) Read More...
Serono (drt-x: SEO and NYSE: SRA) announced today that recruitment in the U.S. is beginning for the Phase III CLARITY study (CLAdRIbine Tablets in Treating MS OrallY Study) of oral cladribine for the treatment of patients with relapsing forms of multiple sclerosis (MS). This multi-national study was successfully initiated outside the U Read More...
US Food and Drug Administration grants priority review status after accepting US regulatory submission for 0.5 mg once-daily Gilenia (fingolimod) US and European Union regulatory submissions completed in December 2009 for Gilenia include more than 4,000 patient years of clinical trial data Basel, February 22, 2010 - Gilenia®* (FTY720, fingolimod) has been granted priority review status by the US Food and Drug Administration (FDA), which accepted the regulatory submission made in December 2009 for this medicine Read More...
Results of the PreCISe Study – which showed that early treatment with Copaxone® (glatiramer acetate, Teva Pharmaceutical Industries) delayed the development of definite multiple sclerosis – have now been published. Dr. Giancarlo Comi (Scientific Institute San Raffaele, Milan) and colleagues presented results of this study at the Annual Meeting of the American Academy of Neurology in 2008, and based on these results, the U Read More...
EMD Serono has announced that it has applied to the U.S. Food and Drug Administration seeking approval to market cladribine as the first oral disease-modifying therapy for relapsing forms of MS. In a large-scale phase 3 clinical trial, cladribine tablets significantly reduced relapse rates and other disease activity in people with relapsing-remitting MS Read More...
